JP2008510453A5 - - Google Patents

Download PDF

Info

Publication number
JP2008510453A5
JP2008510453A5 JP2007516810A JP2007516810A JP2008510453A5 JP 2008510453 A5 JP2008510453 A5 JP 2008510453A5 JP 2007516810 A JP2007516810 A JP 2007516810A JP 2007516810 A JP2007516810 A JP 2007516810A JP 2008510453 A5 JP2008510453 A5 JP 2008510453A5
Authority
JP
Japan
Prior art keywords
peptide
nva
nle
sequence
sekifyv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007516810A
Other languages
English (en)
Japanese (ja)
Other versions
JP5166025B2 (ja
JP2008510453A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/021609 external-priority patent/WO2006009920A2/en
Publication of JP2008510453A publication Critical patent/JP2008510453A/ja
Publication of JP2008510453A5 publication Critical patent/JP2008510453A5/ja
Application granted granted Critical
Publication of JP5166025B2 publication Critical patent/JP5166025B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007516810A 2004-06-17 2005-06-17 エピトープアナログ Expired - Fee Related JP5166025B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US58096204P 2004-06-17 2004-06-17
US58100104P 2004-06-17 2004-06-17
US60/580,962 2004-06-17
US60/581,001 2004-06-17
PCT/US2005/021609 WO2006009920A2 (en) 2004-06-17 2005-06-17 Epitope analogs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008155749A Division JP2008283979A (ja) 2004-06-17 2008-06-13 エピトープアナログ

Publications (3)

Publication Number Publication Date
JP2008510453A JP2008510453A (ja) 2008-04-10
JP2008510453A5 true JP2008510453A5 (https=) 2008-08-07
JP5166025B2 JP5166025B2 (ja) 2013-03-21

Family

ID=35198081

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007516810A Expired - Fee Related JP5166025B2 (ja) 2004-06-17 2005-06-17 エピトープアナログ
JP2008155749A Ceased JP2008283979A (ja) 2004-06-17 2008-06-13 エピトープアナログ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008155749A Ceased JP2008283979A (ja) 2004-06-17 2008-06-13 エピトープアナログ

Country Status (10)

Country Link
US (5) US8202841B2 (https=)
EP (2) EP1765858B1 (https=)
JP (2) JP5166025B2 (https=)
KR (2) KR20100092031A (https=)
AU (1) AU2005265182B2 (https=)
CA (1) CA2571168A1 (https=)
IL (2) IL180101A (https=)
MX (1) MXPA06014768A (https=)
SG (1) SG153827A1 (https=)
WO (1) WO2006009920A2 (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US7178491B2 (en) * 2003-06-05 2007-02-20 Caterpillar Inc Control system and method for engine valve actuator
US20060159689A1 (en) * 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US20060008468A1 (en) * 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US8202841B2 (en) * 2004-06-17 2012-06-19 Mannkind Corporation SSX-2 peptide analogs
EP1773402A2 (en) * 2004-06-17 2007-04-18 Mannkind Corporation Improved efficacy of immunotherapy by integrating diagnostic with therapeutic methods
US20060165711A1 (en) * 2004-12-29 2006-07-27 Bot Adrian I Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes
EP1838342A2 (en) * 2004-12-29 2007-10-03 Mannkind Corporation Methods to bypass cd+4 cells in the induction of an immune response
EP1838338A2 (en) 2004-12-29 2007-10-03 Mannkind Corporation Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
AU2005321898B2 (en) * 2004-12-29 2012-07-19 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
MX2007015933A (es) 2005-06-17 2008-04-21 Mannkind Corp Metodos y composiciones para generar respuestas inmunes multivalentes contra espitopes dominantes y subdominantes, expresados en celulas cancerigenas y estromas tumorales.
CN101687020A (zh) * 2005-06-17 2010-03-31 曼康公司 用于癌症的多价引发-和-增强免疫治疗剂
NZ564359A (en) * 2005-06-17 2011-09-30 Mannkind Corp Analogs of pepetides corresponding to class I MHC-restricted T cell epitopes
US8396671B2 (en) * 2006-02-16 2013-03-12 Microsoft Corporation Cluster modeling, and learning cluster specific parameters of an adaptive double threading model
US20070192033A1 (en) * 2006-02-16 2007-08-16 Microsoft Corporation Molecular interaction predictors
US8706421B2 (en) * 2006-02-16 2014-04-22 Microsoft Corporation Shift-invariant predictions
CN1850855B (zh) * 2006-05-26 2012-08-29 厦门大学 用于免疫或制备单克隆抗体的方法和组合物
WO2008008541A2 (en) * 2006-07-14 2008-01-17 Mannkind Corporation Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes
ES2709176T3 (es) 2006-08-11 2019-04-15 Life Sciences Res Partners Vzw Péptidos inmunogénicos y su uso en trastornos inmunitarios
US8121797B2 (en) * 2007-01-12 2012-02-21 Microsoft Corporation T-cell epitope prediction
EP2129389B1 (en) * 2007-02-15 2014-10-08 MannKind Corporation A method for enhancing t cell response
WO2008118017A2 (en) 2007-03-26 2008-10-02 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Prame derived peptides and immunogenic compositions comprising these
MX2009012635A (es) * 2007-05-23 2012-09-13 Mannkind Corp Vectores multicistronicos y metodos para su diseño.
EP2247306B1 (en) 2008-02-14 2018-04-18 Life Sciences Research Partners VZW Immunogenic control of tumours and tumour cells
AU2010310468A1 (en) * 2009-10-23 2012-05-24 Mannkind Corporation Cancer immunotherapy and method of treatment
CN102869682B (zh) 2009-11-18 2016-10-19 曼康公司 单克隆抗体及其诊断用途
WO2011111392A1 (en) 2010-03-11 2011-09-15 Oncotherapy Science, Inc. Hjurp peptides and vaccines including the same
WO2012023033A2 (en) 2010-08-18 2012-02-23 Purdue Pharma L.P. Improved peptide immunogens
CN103124740B (zh) 2010-09-21 2015-09-02 美国卫生和人力服务部 抗-ssx-2t细胞受体和相关材料及使用方法
ES2924027T3 (es) 2010-11-25 2022-10-04 Imcyse Sa Péptidos inmunogénicos para su uso en la prevención y/o tratamiento de enfermedades infecciosas, enfermedades autoinmunitarias, respuestas inmunitarias a alofactores, enfermedades alérgicas, tumores, rechazo de injerto y respuestas inmunitarias contra vectores virales usados para terapia génica o vacunación génica
WO2012076059A1 (en) * 2010-12-09 2012-06-14 Stichting Het Nederlands Kanker Instituut Immune restricted peptides with increased efficacy
US20140050780A1 (en) 2010-12-23 2014-02-20 Ludwig Institute For Cancer Research Ltd. Liposomal formulation of nonglycosidic ceramides and uses thereof
GB201201511D0 (en) 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
WO2016022363A2 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
JP7109784B2 (ja) 2015-10-23 2022-08-01 プレジデント アンド フェローズ オブ ハーバード カレッジ 遺伝子編集のための進化したＣａｓ９蛋白質
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
JP2020510038A (ja) 2017-03-09 2020-04-02 プレジデント アンド フェローズ オブ ハーバード カレッジ がんワクチン
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
WO2019023680A1 (en) 2017-07-28 2019-01-31 President And Fellows Of Harvard College METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE)
WO2019118949A1 (en) 2017-12-15 2019-06-20 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
WO2020051566A1 (en) * 2018-09-07 2020-03-12 Immunotope, Inc. Vaccines with enhanced immune response and methods for their preparation
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
JP7657726B2 (ja) 2019-03-19 2025-04-07 ザ ブロード インスティテュート，インコーポレーテッド 編集ヌクレオチド配列を編集するための方法および組成物
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
CA3268029A1 (en) * 2022-10-05 2024-04-11 Tscan Therapeutics, Inc. Immunogenic peptides (FRAME), binding proteins recognizing immunogenic peptides (PRAME), and their uses

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5241047A (en) * 1988-12-08 1993-08-31 Biochem Pharma Inc. Synthetic peptides and mixtures thereof for detecting HIV antibodies
US6417165B1 (en) * 1988-03-27 2002-07-09 Ludwig Institute For Cancer Research NY-ESO-1-peptide derivatives, and uses thereof
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
DE4128684A1 (de) * 1991-08-29 1993-03-04 Behringwerke Ag Hcmv-spezifische peptide, mittel dazu und ihre verwendung
US5662907A (en) * 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
ES2276390T3 (es) 1992-11-05 2007-06-16 Sloan-Kettering Institute For Cancer Research Antigeno de membrana especifico de la prostata.
US5747271A (en) * 1992-12-22 1998-05-05 Ludwig Institute For Cancer Research Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of HLA-A2/tyrosinase derived peptides, and methods for treating said individuals
US5620886A (en) * 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US5935818A (en) * 1995-02-24 1999-08-10 Sloan-Kettering Institute For Cancer Research Isolated nucleic acid molecule encoding alternatively spliced prostate-specific membrane antigen and uses thereof
US5874560A (en) 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US5830753A (en) 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US5821122A (en) * 1995-06-07 1998-10-13 Inserm (Institute Nat'l De La Sante Et De La Recherche . .) Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
US6025191A (en) 1995-06-07 2000-02-15 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode a melanoma specific antigen and uses thereof
US6548064B1 (en) * 1997-05-05 2003-04-15 Ludwig Institute For Cancer Research Isolated peptides consisting of amino acid sequences found in SSX or NY-ESO-1 molecules, which bind to HLA molecules
US6025470A (en) * 1997-06-23 2000-02-15 Ludwig Institute For Cancer Research Isolated nona- and decapeptides which bind to HLA molecules, and the use thereof
EP2286831A1 (en) 1997-07-10 2011-02-23 Mannkind Corporation A method of inducing a CTL response
US6994851B1 (en) * 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6576755B1 (en) * 1997-09-10 2003-06-10 Zymogenetics, Inc. Beta-defensins
US20030138808A1 (en) 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
US6709844B1 (en) * 2000-11-16 2004-03-23 Mannkind Corporation Avoidance of undesirable replication intermediates in plasmid propagation
US20020072493A1 (en) * 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
GB9818938D0 (en) * 1998-08-28 1998-10-21 Alpharma As Bioactive peptides
US6777388B1 (en) * 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
NZ513482A (en) 1999-02-05 2003-08-29 Univ Melbourne T helper cell epitodes derived from canine distemper virus for producing an immune response in an animal
US7157091B1 (en) * 1999-06-18 2007-01-02 Ludwig Institute For Cancer Research MAGE-A1 peptides presented by HLA class II molecules
WO2001034631A2 (en) * 1999-11-05 2001-05-17 Axonyx, Inc. PEPTIDE ANALOGS AND MIMETICS SUITABLE FOR IN VIVO USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ABNORMAL PROTEIN FOLDING INTO AMYLOID, AMYLOID-LIKE DEPOSITS OR β-SHEET RICH PATHOLOGICAL PRECURSOR THEREOF
US6605711B1 (en) 1999-11-15 2003-08-12 Ludwig Institute For Cancer Research NY-ESO-1 peptide derivatives, and uses thereof
CA2390659C (en) * 1999-11-15 2010-03-02 Ludwig Institute For Cancer Research Ny-eso-1 peptide derivatives, and uses thereof
AU1661201A (en) * 1999-11-18 2001-05-30 Epimmune, Inc. Heteroclitic analogs and related methods
EP1118860A1 (en) 2000-01-21 2001-07-25 Rijksuniversiteit te Leiden Methods for selecting and producing T cell peptide epitopes and vaccines incorporating said selected epitopes
CN1452634A (zh) 2000-02-23 2003-10-29 埃皮缪纳股份有限公司 Hla结合肽及其用途
CA2405568A1 (en) * 2000-04-05 2001-10-18 North Carolina State University Prion-binding peptidic ligands and methods of using same
US20030215425A1 (en) 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
US6861234B1 (en) * 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
JP2005505242A (ja) 2001-03-07 2005-02-24 マンカインド コーポレイション 癌用抗新生血管系調製物
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
US20030148973A1 (en) * 2001-05-23 2003-08-07 Peter Emtage MAGE-A1 peptides for treating or preventing cancer
US20030017134A1 (en) * 2001-06-19 2003-01-23 Technion Research And Development Foundation Ltd. Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
US8637305B2 (en) * 2001-11-07 2014-01-28 Mannkind Corporation Expression vectors encoding epitopes of target-associated antigens and methods for their design
WO2003104428A2 (en) * 2002-01-21 2003-12-18 Vaccinex, Inc. Gene differentially expressed in breast and bladder cancer and encoded polypeptides
JP2005528338A (ja) * 2002-01-29 2005-09-22 アンティセンス ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング 「黒色腫阻害活性物質」（ｍｉａ）を阻害する方法
US6992176B2 (en) * 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
US8802618B2 (en) 2002-03-08 2014-08-12 Board Of Regents, The University Of Texas System Controlled modulation of amino acid side chain length of peptide antigens
WO2004011483A2 (en) * 2002-07-31 2004-02-05 Ludwig Institute For Cancer Research Isolated, ssx-2 and ssx-2 related peptides useful as hla binders and ctl epitopes, and uses thereof
AU2003256912A1 (en) * 2002-08-16 2004-03-03 Yeda Research And Development Co. Ltd. Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
WO2004022709A2 (en) 2002-09-06 2004-03-18 Mannkind Corporation Epitope sequences
WO2004030616A2 (en) * 2002-09-17 2004-04-15 Antigen Express, Inc. Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES
DE602004028468D1 (de) * 2003-06-17 2010-09-16 Mannkind Corp Haltung von immunantworten gegen mhc-klasse-i-beschränkte epitope, für prophylaktische oder therapeutische zwecke
AU2004249254B2 (en) 2003-06-17 2010-07-08 Mannkind Corporation Combinations of tumor-associated antigens for the treatment of various types of cancers
US8202841B2 (en) 2004-06-17 2012-06-19 Mannkind Corporation SSX-2 peptide analogs
EP1773402A2 (en) * 2004-06-17 2007-04-18 Mannkind Corporation Improved efficacy of immunotherapy by integrating diagnostic with therapeutic methods
US20060159689A1 (en) * 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US20060008468A1 (en) 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
EP1838338A2 (en) * 2004-12-29 2007-10-03 Mannkind Corporation Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
US20060165711A1 (en) * 2004-12-29 2006-07-27 Bot Adrian I Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes
AU2005321898B2 (en) * 2004-12-29 2012-07-19 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
US9469902B2 (en) 2014-02-18 2016-10-18 Lam Research Corporation Electroless deposition of continuous platinum layer
EP3636238B1 (en) 2018-10-12 2021-04-28 Liko Research & Development AB Gates with transition ramps for overhead lifting rails

Similar Documents

Publication Publication Date Title
JP2008510453A5 (https=)
JP2008543314A5 (https=)
MX2022011411A (es) Proteinas de union a antigeno que se unen especificamente a mage-a.
DE60332645D1 (de) Ii-key/antigene epitop-hybrid-peptid-vakzine
GB2439474A (en) LI-Key/Antigenic epitope hybrid peptide vaccines
NZ597685A (en) Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
JP2018509935A5 (https=)
JP2006187292A5 (https=)
DE60030450D1 (de) Von MUC-1 abgeleitete Peptide
JP2004000251A5 (https=)
NZ606427A (en) Extended recombinant polypeptides and compositions comprising same
PH12012502372A1 (en) Hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same
AU2003239659A8 (en) Peptide epitopes common to antigens of the same multigene family
JP2021520818A5 (https=)
JP2017502003A5 (https=)
JP2006514820A5 (https=)
JP2002517193A5 (https=)
JP2008521795A5 (https=)
ATE412745T1 (de) Antiangiogene peptide vom n-terminus von endostatin
WO2003106616A3 (en) $ G (B) MICROGLOBULIN MEMBRANE ANCHORED COVALENTLY LINKED TO PEPTIDE EPITOPES OF CLASS I MHC
DE60323634D1 (de) Nichtimmunsuppressive immunogene oder vakzinzusammensetzung enthaltend ein mutiertes e7-protein vom humanen papilloma-virus hpv-16
ATE357526T1 (de) Modifizierte hcv peptid-impfstoffe
NZ591133A (en) Novel melanoma antigen peptide and uses thereof
NZ507983A (en) A polypeptide comprising the amino acid of an n- terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
DE602005015368D1 (de) Immunogenes polypeptid bestehend aus optimierten kryptischen peptiden aus tumorantigenen und seine verwendungen